|Bid||35.35 x 1000|
|Ask||38.31 x 900|
|Day's Range||38.09 - 38.56|
|52 Week Range||28.49 - 42.82|
|Beta (3Y Monthly)||-0.12|
|PE Ratio (TTM)||27.18|
|Forward Dividend & Yield||0.29 (0.70%)|
|1y Target Est||28.03|
Dr. Reddy's Laboratories (NYSE:RDY) reported its quarterly earnings figures on Friday, bringing in a profit that increased year-over-year and revenue that came in ahead of what Wall Street projected in its consensus guidance, yet RDY stock took a step back.The India-based business announced that for its fourth quarter of its fiscal 2019, it raked in earnings of 38 cents per ADS, which was roughly 12 cents higher than the company's profit from the same period in its fiscal 2018. Its revenue also impressed, coming in at $581 million for the three-month period.This amount was 13.7% higher than it was during the year-ago quarter for Dr. Reddy's, while also topping the Zacks Investment Research, which foresaw the company raking in sales of $565.45 million. Revenue from the company's Global Generics segment was up 9% year-over-year, while the Pharmaceutical Services and Active Ingredients segment saw sales surge 8% year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDr. Reddy's added that its Proprietary Products segment gained 139% year-over-year. For the fiscal year, the company brought in sales of $2.2 billion, gaining 8.3% when compared to the year-ago quarter.Earnings for its fiscal 2019 tallied up to $1.64 per ADS, marking a whopping gain of 92.9% when compared to the year-ago quarter.RDY stock is down about 1.6% on Friday despite the company unveiling quarterly earnings results that came in ahead of what Wall Street called for in its consensus estimate. Shares had been gaining 0.2% during pre-market trading. More From InvestorPlace * 7 Stocks to Buy that Lost 10% Last Week * 6 Chinese Stocks That Could Pop On a Trade Deal * 10 Retirement Stocks That Won't Wilt in a Bear Market Compare Brokers The post Dr. Reddy's Laboratories Earnings: RDY Stock Dips Despite Q4 Beat appeared first on InvestorPlace.
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
Dr. Reddy’s Laboratories Ltd. today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S.
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the U.S.
NEW YORK , May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City ...
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
With economic growth slowing worldwide in 2019, investors looking for growth sources have been forced to get creative. Ongoing concerns about the outcome of the Sino-American trade war have clouded the outlook for the Chinese market, but India has the sixth-largest economy in the world and is expected to grow by 7.3 percent this year, according to the International Monetary Fund. Unreliable Numbers? Unfortunately for India investors, growth projections are dropping worldwide — and India may be no exception.
Dr. Reddy’s Laboratories Limited , through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% in the United States, to Encore Dermatology.
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis Tablets in the United States market, approved by the U.S.
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone® sublingual film, in the United States market.